Latest News

  • Silicon Therapeutics Announces Members of Scientific Advisory Board

    BOSTON, DEC. 10, 2020 — Silicon Therapeutics, a privately-held, integrated therapeutics company with a pioneering drug discovery platform based on physics-driven molecular simulations, today announced the members of the Silicon Therapeutics scientific advisory board (SAB), which include Dr. Elliot L. Chaikof, Dr. Timothy P. Heffernan, Dr. Sun Hur, Dr. Pasi A. Jänne and Dr. Lijun Sun. The Silicon Therapeutics

  • Silicon Therapeutics Announces Dosing of First Patient in Phase 1 Open-Label Clinical Trial of SNX281 for Advanced Solid Tumors or Lymphoma

    SNX281 is a novel systemically available small molecule agonist of Stimulator of Interferon Genes (STING) and the company’s first investigational candidate to enter the clinic The study will be comprised of two treatment arms, one evaluating SNX281 as a monotherapy, and the other evaluating SNX281 in combination with the PD-1 inhibitor pembrolizumab BOSTON, NOV. 23,

  • Silicon Therapeutics Supports Five Researchers Through Open Science Fellows Program

    BOSTON, OCT. 21, 2020 — Silicon Therapeutics, a privately-held, fully integrated drug design, discovery and development company focused on small molecule therapeutics, today is pleased to introduce the 2020 members of the Silicon Therapeutics Open Science Fellows Program, which include Dr. Lilian Chong, Dr. Heather Kulik, Dr. Tom Kurtzman, Dr. David Mobley and Dr. Michael Shirts. Research areas include

All Press Releases

Upcoming Events

All Events